{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:06:26Z","timestamp":1791363986251,"version":"4.3.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UKRI Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.annonc.2025.07.005","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:36:45Z","timestamp":1752712605000},"page":"1331-1341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data"],"prefix":"10.1016","volume":"36","author":[{"given":"C.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8942-9836","authenticated-orcid":false,"given":"P.","family":"Dutey-Magni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.R.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1322-4671","authenticated-orcid":false,"given":"J.E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Amos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-7012","authenticated-orcid":false,"given":"D.C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3695-3167","authenticated-orcid":false,"given":"D.","family":"Matheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Millman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0166-1700","authenticated-orcid":false,"given":"M.K.B.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-1371","authenticated-orcid":false,"given":"M.R.","family":"Sydes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2827-6634","authenticated-orcid":false,"given":"L.C.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.D.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.W.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7359-7114","authenticated-orcid":false,"given":"A.","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.annonc.2025.07.005_bib1","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.juro.2009.01.047","article-title":"Metabolic complications of androgen deprivation therapy for prostate cancer","volume":"181","author":"Saylor","year":"2009","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.annonc.2025.07.005_bib2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/00365599309182280","article-title":"The effects of orchidectomy on skeletal metabolism in metastatic prostate cancer","volume":"27","author":"Clarke","year":"1993","journal-title":"Scand J Urol Nephrol"},{"issue":"6","key":"10.1016\/j.annonc.2025.07.005_bib3","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.annonc.2025.07.005_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.annonc.2025.07.005_bib5","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1464-410X.2009.08483.x","article-title":"Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values","volume":"104","author":"Wadhwa","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.annonc.2025.07.005_bib6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bone.2019.06.005","article-title":"Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy","volume":"127","author":"Dalla Via","year":"2019","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.annonc.2025.07.005_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"issue":"10024","key":"10.1016\/j.annonc.2025.07.005_bib8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.annonc.2025.07.005_bib9","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.07.005_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2020.100311","article-title":"Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group","volume":"25","author":"Brown","year":"2020","journal-title":"J Bone Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.07.005_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.annonc.2025.07.005_bib12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/JU.0000000000001375","article-title":"Advanced prostate cancer: AUA\/ASTRO\/SUO guideline Part I","volume":"205","author":"Lowrance","year":"2021","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.annonc.2025.07.005_bib13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.annonc.2025.07.005_bib14","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.annonc.2025.07.005_bib15","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.07.005_bib16","doi-asserted-by":"crossref","first-page":"1093i","DOI":"10.1093\/ije\/dyx015","article-title":"Data Resource Profile: Hospital Episode Statistics Admitted Patient Care (HES APC)","volume":"46","author":"Herbert","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.annonc.2025.07.005_bib17","author":"Murray"},{"issue":"8","key":"10.1016\/j.annonc.2025.07.005_bib18","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1016\/S2589-7500(22)00122-4","article-title":"Data provenance and integrity of health-care systems data for clinical trials","volume":"4","author":"Murray","year":"2022","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.annonc.2025.07.005_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2019.101628","article-title":"Identifying skeletal-related events for prostate cancer patients in routinely collected hospital data","volume":"63","author":"Parry","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"10.1016\/j.annonc.2025.07.005_bib20","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.07.005_bib21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/1536867X1701700212","article-title":"stpm2cr: a flexible parametric competing risks model using a direct likelihood approach for the cause-specific cumulative incidence function","volume":"17","author":"Mozumder","year":"2017","journal-title":"Stata J"},{"issue":"21","key":"10.1016\/j.annonc.2025.07.005_bib22","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1002\/sim.1915","article-title":"Sample size formula for proportional hazards modelling of competing risks","volume":"23","author":"Latouche","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.annonc.2025.07.005_bib23","series-title":"STANDSURV: Stata module to compute standardized (marginal) survival and related functions [computer program]","author":"Lambert","year":"2021"},{"key":"10.1016\/j.annonc.2025.07.005_bib24","author":"Lambert"},{"key":"10.1016\/j.annonc.2025.07.005_bib25","author":"Islam"},{"issue":"1","key":"10.1016\/j.annonc.2025.07.005_bib26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12874-022-01666-x","article-title":"Estimating causal effects in the presence of competing events using regression standardisation with the Stata command standsurv","volume":"22","author":"Syriopoulou","year":"2022","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10.1016\/j.annonc.2025.07.005_bib27","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jclinepi.2012.09.017","article-title":"A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions","volume":"66","author":"Latouche","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"42","key":"10.1016\/j.annonc.2025.07.005_bib28","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1093\/eurheartj\/ehu131","article-title":"Competing risks analyses: objectives and approaches","volume":"35","author":"Wolbers","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.annonc.2025.07.005_bib29","series-title":"UK Health Accounts: reference tables 2019","year":"2021"},{"key":"10.1016\/j.annonc.2025.07.005_bib30","series-title":"Payment by Results data assurance framework: key findings from the 2012\/13 programme","year":"2013"},{"key":"10.1016\/j.annonc.2025.07.005_bib31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.12688\/f1000research.23316.2","article-title":"Use of routinely collected data in a UK cohort of publicly funded randomised clinical trials","volume":"9","author":"McKay","year":"2020","journal-title":"F1000Res"},{"issue":"7","key":"10.1016\/j.annonc.2025.07.005_bib32","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1464-410X.2003.04471.x","article-title":"Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation","volume":"92","author":"Hussain","year":"2003","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.annonc.2025.07.005_bib33","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/pcan.2013.35","article-title":"RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients","volume":"16","author":"Kachnic","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.annonc.2025.07.005_bib34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1464-410X.1992.tb15461.x","article-title":"Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer","volume":"69","author":"Clarke","year":"1992","journal-title":"Br J Urol"},{"issue":"1","key":"10.1016\/j.annonc.2025.07.005_bib35","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10147-016-1037-2","article-title":"A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial","volume":"22","author":"Kamba","year":"2017","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.07.005_bib36","first-page":"CD006250","article-title":"Bisphosphonates for advanced prostate cancer","volume":"12","author":"Macherey","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.annonc.2025.07.005_bib37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"J Am Med Assoc"},{"issue":"12","key":"10.1016\/j.annonc.2025.07.005_bib38","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.07.005_bib39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamaoncol.2020.6353","article-title":"Association of osteonecrosis of the jaw with zoledronic acid treatment for bone metastases in patients with cancer","volume":"7","author":"Van Poznak","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.07.005_bib40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"17","author":"Gregson","year":"2022","journal-title":"Arch Osteoporos"},{"issue":"8","key":"10.1016\/j.annonc.2025.07.005_bib41","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.annonc.2025.07.005_bib43","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.euo.2024.01.016","article-title":"Risk of fractures and falls in men with advanced or metastatic prostate cancer receiving androgen deprivation therapy and treated with novel androgen receptor signalling inhibitors: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Jones","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.07.005_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.2467","article-title":"Bone-modifying agents in patients with high-risk metastatic castration-sensitive prostate cancer treated with abiraterone acetate","volume":"7","author":"Fukuokaya","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425008543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425008543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:38:25Z","timestamp":1780313905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425008543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0923753425008543"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.07.005","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}